Key developments in the life sciences sector highlight significant changes in regulatory frameworks governing the cross-border flow of genomic data and clinical trial data. The US Department of Justice’s Data Security Program (DSP) is fully active, enforcing strict compliance measures that restrict transactions involving human genomic and other sensitive data. Additionally, the House Select Committee on the Chinese Communist Party has initiated inquiries into US pharmaceutical companies’ clinical trials in China, raising concerns about data security. These evolving regulations, including several legislative acts aimed at screening investments, are complicating the landscape for both US and Chinese biotech firms, with heightened scrutiny and escalating compliance obligations. As a result, companies are adjusting their agreements and practices to meet the stringent requirements imposed by the DSP while navigating potential conflicts with Chinese laws on data management. This dual regulatory challenge necessitates sophisticated handling of data flows and compliance strategies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.morganlewis.com/pubs/2026/07/dojs-bulk-sensitive-personal-data-rule-a-cross-border-compliance-imperative-for-the-life-sciences-industry
